BioCurex breast cancer test shows 100% sensitivity
This article was originally published in Clinica
Executive Summary
BioCurex's HistoRECAF diagnostic test has been shown to have 100% sensitivity in detecting cancer in breast biopsy samples. The test measures over-expression of the alpha-fetoprotein (AFP) receptor (RECAF). Furthermore, the study, carried out at the Hospital de Clinicas de las Fuerzas Armadas in Montevideo, Uruguay, found no false positives among samples from patients with dysplasias or benign tumours.